文献速递骨软组织肉瘤与黑色素瘤

晚期黑色素瘤患者短期CTLA-4阻断后直接序贯PD-1阻断:单中心经验

Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience.
PubMed 文献 · Ann Oncol · 2017-01-01

这项单中心回顾性分析纳入40例晚期黑色素瘤患者,接受2周期伊匹木单抗(3 mg/kg q3wk)后直接序贯纳武利尤单抗(3 mg/kg q2wk)或帕博利珠单抗(2 mg/kg q3wk)。3-4级治疗相关不良事件发生率为38%,最佳总缓解率为55%(95%CI 39-70),疾病控制率为75%(95%CI 59-87)。作者认为短期CTLA-4阻断后直接序贯PD-1阻断与同步联合治疗相比可能疗效相似但毒性更低,需前瞻性随机对照试验进一步研究。

要点

  • 40例晚期黑色素瘤患者接受2周期伊匹木单抗后直接序贯PD-1阻断。
  • 3-4级治疗相关不良事件发生率为38%。
  • 最佳总缓解率55%(95%CI 39-70),疾病控制率75%(95%CI 59-87)。

核心结论

  • 短期CTLA-4阻断后直接序贯PD-1阻断与同步抗CTLA-4联合抗PD-1治疗相比可能疗效相似但毒性更低。
  • 这些结果需前瞻性随机对照临床试验进一步研究。

研究设计与样本

  • 单中心回顾性分析,纳入40例晚期黑色素瘤患者。
  • 患者接受2周期抗CTLA-4治疗(第0天和第21天,伊匹木单抗3 mg/kg q3wk),直接序贯抗PD-1治疗(自第22天开始,纳武利尤单抗3 mg/kg q2wk或帕博利珠单抗2 mg/kg q3wk)。
  • 治疗相关不良事件从电子病历收集,按CTCAE 4.03标准评分。
  • 总体缓解采用RECIST 1.1评估CT扫描,采用EORTC标准评估PET扫描。

主要发现

  • 40例患者中29/40接受帕博利珠单抗,11/40接受纳武利尤单抗。
  • 中位随访51周(范围4-63周),最短随访26周。
  • 3-4级治疗相关不良事件发生于38%的患者。
  • 最佳总缓解率为55%(95%CI 39-70),疾病控制率为75%(95%CI 59-87)。
  • 缓解患者中82%观察到持续缓解。

局限性

  • 原文为单中心回顾性分析。
  • 这些结果需前瞻性随机对照临床试验进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combination of T cell checkpoint blockade by CTLA-4- and PD-1-blockade is one of the most promising therapies in patients with advanced melanoma. It induces superior response rates when compared with single-agent therapy, but at the cost of a high percentage of grade 3 and 4 adverse events (AEs). This combination therapy was until July 2016 not available in the Netherlands, which prompted several physicians to treat patients with less than standard numbers of courses of ipilimumab followed directly by nivolumab or pembrolizumab. PATIENTS AND METHODS: In this retrospective analysis, patients were included who were treated with two courses (day 0 and 21) anti-CTLA-4 (ipilimumab 3 mg/kg q3wk), directly followed by anti-PD-1 (starting at day 22 with nivolumab 3mg/kg q2wk or pembrolizumab 2 mg/kg q3wk). Data on treatment-related AEs were collected from electronic patient records and scored according to CTCAE 4.03 criteria. Overall response was evaluated using RECIST 1.1 for CT-scans and EORTC criteria for PET-scans. RESULTS: Forty advanced melanoma patients could be included (29/40 pembrolizumab, 11/40 nivolumab). Median follow-up (FU) was 51 weeks (range: 4-63 weeks) with a minimum FU of 26 weeks. Treatment-related AEs of grade 3 and 4 occurred in 38% of the patients. The best overall response rate (BORR) was 55% (95% CI 39-70) and disease control rate was 75% (95% CI 59-87). Ongoing responses were observed in 82% of responding patients. CONCLUSION: Treatment with short-term CTLA-4 blockade directly followed by PD-1 blockade may have similar efficacy but potentially lower toxicity when compared with concurrent therapy with anti-CTLA-4 and anti-PD-1. These results warrant further investigation in a prospective randomized controlled clinical trial.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Meerveld-Eggink A, Rozeman EA, Lalezari F, et al. Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience. Ann Oncol. 2017. PMID: 28158487. doi:10.1093/annonc/mdw692

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。